Christopher Chen
Stock Analyst at Robert W. Baird
(3.18)
# 2,581
Out of 4,707 analysts
5
Total ratings
100%
Success rate
50.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Maintained: Buy | $28 → $52 | $33.88 | +53.48% | 2 | Aug 18, 2026 | |
| LRMR Larimar Therapeutics | Maintained: Buy | $5 | $4.08 | +22.70% | 1 | Jun 30, 2026 | |
| DFTX Definium Therapeutics | Maintained: Buy | $37 → $57 | $38.23 | +49.10% | 2 | Jun 23, 2026 |
Amylyx Pharmaceuticals
Aug 18, 2026
Maintained: Buy
Price Target: $28 → $52
Current: $33.88
Upside: +53.48%
Larimar Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: $5
Current: $4.08
Upside: +22.70%
Definium Therapeutics
Jun 23, 2026
Maintained: Buy
Price Target: $37 → $57
Current: $38.23
Upside: +49.10%